Curriculum Vitaes
  1. Researcher Search Results
  2. Sato Harunobu

Sato Harunobu

  (佐藤 美信)

Profile Information

Affiliation
Professor, Fujita Health University
Degree
Doctor(Mar, 1996, Fujita Health University)
Researcher number
50329736
ORCID ID
 https://orcid.org/0000-0003-4637-8853
J-GLOBAL ID
200901029590935073
researchmap Member ID
5000024804

Research Interests

 4

Research Areas

 3

Awards

 7
More

Papers

 77
  • Hiroki Tani, Hiroyuki Kato, Yukio Asano, Masahiro Ito, Satoshi Arakawa, Masahiro Shimura, Daisuke Koike, Takayuki Ochi, Kenshiro Kamio, Toki Kawai, Hironobu Yasuoka, Takahiko Higashiguchi, Yoshiki Kunimura, Kazuma Horiguchi, Hidetoshi Nagata, Yuka Kondo, Yutaro Kato, Tsunekazu Hanai, Harunobu Sato, Akihiko Horiguchi
    Gan to kagaku ryoho. Cancer & chemotherapy, 50(8) 929-932, Aug, 2023  Peer-reviewed
    We report a case of a woman in her 70s who underwent conversion surgery after FOLFIRINOX, followed by radiation therapy for initially locally advanced unresectable pancreatic cancer. She visited her local doctor with a chief complaint of upper abdominal pain. Contrast-enhanced CT scan of the abdomen revealed an irregular mass invading the superior mesenteric artery, and the first and second jejunal arteries(>180°)in the pancreatic uncinate region. Based on imaging, she was diagnosed as UR-LA(sm), cT4N0M0, cStage Ⅲ pancreatic cancer, and underwent 5 courses of modified FOLFIRINOX. Radiation therapy of 50.4 Gy was added for local control, and CA19-9 decreased from 394.1 U/mL to 10.5 U/mL. The treatment effect was judged as RECIST: partial response. The tumor was considered to be potentially curative, and a subtotal stomach preserving pancreaticoduodenectomy was performed 8 months after the initial treatment. The tumor was found to be 3× 2 mm in size, pStage ⅠA, R0, and the response to preoperative chemotherapy: Evans Grade Ⅲ. The patient is alive at 5 months postoperatively without recurrence.
  • Eita Joki, Hiroyuki Kato, Hiroki Tani, Yukio Asano, Masahiro Ito, Satoshi Arakawa, Masahiro Shimura, Daisuke Koike, Takayuki Ochi, Kenshiro Kamio, Toki Kawai, Hironobu Yasuoka, Takahiko Higashiguchi, Yoshiki Kunimura, Kazuma Horiguchi, Hidetoshi Nagata, Yuka Kondo, Harunobu Sato, Yutaro Kato, Tsunekazu Hanai, Akihiko Horiguchi
    Gan to kagaku ryoho. Cancer & chemotherapy, 50(8) 933-936, Aug, 2023  Peer-reviewed
    We report a case of a patient with sigmoid colon cancer and multiple liver metastases who underwent hepatectomy after chemotherapy and pathological results showed complete remission. However, after chemotherapy was discontinued, the patient developed a local recurrence of the liver metastasis and underwent rehepatectomy. The patient came to our hospital with lower abdominal pain. Colonoscopy revealed a circumferential type Ⅱ, well-differentiated adenocarcinoma. Laparoscopic sigmoidectomy with lymph node dissection was performed. Postoperative CT scan showed multiple liver metastases at S5, S7, and S8. 11 cycles of bevacizumab plus modified FOLFOX(mFOLFOX)were subsequently performed. The liver metastases shrank at all sites, and the patient underwent right hepatectomy. The resected specimen was considered to be in complete remission, with no evidence of viable malignant cells. Postoperatively, bevacizumab plus mFOLFOX was resumed for 6 cycles and the patient remained in remission. However, 3 months after stopping chemotherapy and 1 year and 6 months after hepatectomy, a follow-up CT scan showed local recurrence of the liver edge, and a diagnosis of local recurrence of liver metastasis was made, and a partial hepatectomy was performed. The patient is recurrence-free and resuming modified FOLFOX 9 months after surgery.
  • Harunobu Sato, Koichi Suda, Yoshikazu Koide, Yukio Asano, Satoshi Arakawa, Hiroyuki Kato, Masahiro Shimura, Daisuke Koike, Kenshiro Kamiya, Eiki Kawai, Takahiko Higashiguchi, Akihiko Horiguchi
    Gan to kagaku ryoho. Cancer & chemotherapy, 49(13) 1423-1425, Dec, 2022  Peer-reviewedLead author
    The outcomes of 88 patients with lower rectal T2 cancer who underwent radical A surgery(T2)were compared with those of 340 patients with T3 or T4a cancer(T3/T4a)and 51 patients with T1 cancer(T1). The rates of all lymph node(LN) metastasis, paraintestinal LN metastasis, intermediate and main LN metastasis, and lateral LN metastasis in T2 were all significantly lower than in T3/T4a and not different from those in T1. The recurrence rate of T2 was 15.9%, significantly lower than that of T3/T4a and not different from that of T1. Fifty percent of T2 recurrences were observed after 30 months postoperatively, significantly higher than that of T3/T4a and not different from that of T1. The 5-year survival rate of T2 was significantly higher than that of T3/T4a and did not differ from that of T1. In lower rectal T2, cancer LN dissection similar to that in T1 is appropriate, and high preoperative serum CA19-9 level is a risk factor for recurrence, suggesting the need for follow-up after 30 months postoperatively to take recurrence into consideration.
  • Hiroyuki Kato, Yukio Asano, Masahiro Ito, Satoshi Arakawa, Masahiro Shimura, Daisuke Koike, Takayuki Ochi, Hironobu Yasuoka, Toki Kawai, Takahiko Higashiguchi, Hiroki Tani, Yoshiki Kunimura, Yuka Kondo, Hidetoshi Nagata, Harunobu Sato, Akihiko Horiguchi
    World journal of surgical oncology, 20(1) 278-278, Sep 3, 2022  Peer-reviewed
    In this report, we describe a case of highly advanced hepatocellular carcinoma with tumor thrombosis extending into the main portal vein of the pancreas that was successfully treated with adjuvant lenvatinib after right hepatic resection with thrombectomy. A 70-year-old woman was referred from the clinic because of elevated hepatobiliary enzymes. The patient was positive for the hepatitis B virus antigen at our hospital. The tumor markers were highly elevated with alpha-fetoprotein (14.5 U/mL) and protein induced by vitamin K absence (PIVKAII) (1545 ng/mL), suggesting hepatocellular carcinoma. Dynamic abdominal computed tomography showed an early enhanced tumor approximately 6 cm in size and portal vein tumor thrombosis filling the main portal vein, but not extending into the splenic or superior mesenteric vein (SMV). On magnetic resonance imaging 1 week after CT, portal vein tumor thrombosis had extended to the confluence of the splenic vein with the SMV, indicating rapid tumor growth. Thus, we performed emergent right hepatectomy with tumor thrombectomy. Postoperatively, we treated the patient with lenvatinib for a tumor reduction surgery. Fortunately, the patient was alive 2 years postoperatively without recurrence. This case report suggests that a favorable outcome may be achieved with multidisciplinary treatment including resection and postoperative treatment with lenvatinib.
  • Koji Masumori, Kotaro Maeda, Tsunekazu Hanai, Harunobu Sato, Yoshikazu Koide, Hiroshi Matsuoka, Hidetoshi Katsuno, Tomoyoshi Endo, Yeongcheol Cheong, Ichiro Uyama
    Fujita medical journal, 8(3) 67-72, Aug, 2022  Peer-reviewed
    OBJECTIVES: Surgical site infection (SSI) is a problematic complication after stoma closure. The purse string suture (PSS) technique eliminates this problem, but the area takes longer to heal. The present retrospective study was performed to evaluate the usefulness of a vacuum-assisted closure (VAC) system for the promotion of wound healing after stoma closure. METHODS: Consecutive patients undergoing stoma closure with the PSS technique were divided into two groups: those treated with and without use of the VAC system. The volume of dead space and the size of the wound were measured after stoma closure in both groups. The same measurements were performed on days 3 and 7 after closure. The time needed for wound closure was also examined in both groups. Outcomes were also evaluated according to age, body mass index, operative time, bleeding volume, wound consistency, patient satisfaction, perioperative inflammatory response, occurrence of SSI, and hospitalization days. RESULTS: The VAC group comprised 31 patients, and the non-VAC group comprised 34 patients. The volume of dead space on days 3 and 7 after closure was significantly smaller in the VAC group than in the non-VAC group (P=0.006 and P<0.001, respectively). The number of SSIs was significantly lower in the VAC group than in the non-VAC group (P=0.014). CONCLUSION: The dead space volume on days 3 and 7 after stoma closure with PSS significantly decreased by using the VAC system. The incidence of SSI after stoma closure also significantly decreased by using the VAC system.
More

Misc.

 204

Books and Other Publications

 4
  • 日本消化器外科学会, 消化器外科専門医テキスト制作委員会 (Role: Contributor, 27. 肛門良性疾患)
    一般社団法人 日本消化器外科学会, Jul, 2023
  • (Role: Contributor)
    Apr, 2023 (ISBN: 9784830623455)
  • 日本消化器外科学会, 消化器外科専門医テキスト制作委員会 (Role: Contributor, 肛門良性疾患)
    一般社団法人 日本消化器外科学会, Feb, 2020 (ISBN: 9784991132100)
  • 武藤, 徹一郎, 渡辺, 英伸, 杉原, 健一, 多田, 正大 (Role: Contributor, StageⅡ大腸癌に対する補助化学療法-臨床試験からみたハイリスク因子)
    日本メディカルセンター, Jan, 2010 (ISBN: 4888751560)

Presentations

 803
More

Professional Memberships

 17
More

Research Projects

 1

Social Activities

 3
To the list screen